In a large phase 2 trial assigning 333 r/r AML patients, quizartinib as a single agent achieved a cCR rate of 50% in FLT3-ITD positive AML but a CR rate of only 3% due to ongoing treatment-related cytopenia likely caused by additional inhibition of KIT [44]. This evidence concerns the gene KIT and acute myeloid leukemia.